Results 91 to 100 of about 24,077 (195)

Histamine and Serotonin Levels in Bone Marrow Stem Cells Niche as Potential Biomarkers of Systemic Mastocytosis and Myeloproliferative Disorders. [PDF]

Stem Cell Rev Rep, 2023
Janus T, Korbal U, Żukowski M, Lewosiuk A, Koper K, Żukowska A, Brzeźniakiewicz-Janus K.   +6 more
europepmc   +1 more source

H Syndrome Associated With Pure Red Cell Aplasia, Rosai–Dorfman Disease, and Sensorineural Hearing Loss: Phenotypic Variability in Three Children With the Same SLC29A3 Mutation

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT H syndrome is a rare autosomal recessive disorder caused by mutations in the SLC29A3 gene. We report three pediatric patients with a homozygous c.1309G>A (p.Gly437Arg) mutation presenting with distinct phenotypic variations. These cases expand the clinical spectrum and emphasize the importance of early genetic diagnosis and family counseling.
Mohammad Najajrah, Hadeel I. Bouzia, Nermin K. Darawi, Fatima S. Hajjaj, Nour H. Moosa, Noor M. Awad   +5 more
wiley   +1 more source

Covert Brain Infarcts in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders. [PDF]

J Clin Med, 2021
Kuznetsova PI, Raskurazhev AA, Konovalov RN, Krotenkova MV, Chechetkin AO, Lagoda OV, Melikhyan AL, Tanashyan MM.   +7 more
europepmc   +1 more source

Extracellular Vesicles in Acute Myeloid Leukemia: Opportunities and Obstacles for Therapeutic Advancement

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 8, August 2026.
Acute myeloid leukemia (AML) is a disease characterized by uncontrolled proliferation and blocked maturation of hematopoietic stem and progenitor cells. Despite progress in its clinical management, many patients continue to relapse or show limited response to standard therapies, emphasizing the need for novel, safe, and more effective targeted ...
Rongrong Hu, Zaker Ataullev, Luping Lou
wiley   +1 more source

Myelodysplastic/myeloproliferative disorders

Haematologica, 2008
Luca Malcovati, Mario Cazzola
doaj   +1 more source

Inhibitory HLA‐C/KIR2DL2 Interactions and KIR Allelic Polymorphisms Are Associated With Susceptibility to Philadelphia Chromosome‐Negative Myeloproliferative Neoplasms

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Background Immune surveillance is increasingly recognized as a determinant of clonal selection in Philadelphia chromosome‐negative myeloproliferative neoplasms (MPN). While HLA‐restricted adaptive immune effects have been described, the contribution of inherited variation in natural killer (NK)‐cell regulatory pathways remains less well ...
Velizar Shivarov, Gergana Tsvetkova, Evgueniy Hadjiev, Milena Ivanova   +3 more
wiley   +1 more source

Association of Frailty With Transfusions, Hospitalizations, and Survival in Patients With Myelodysplastic Syndrome Initiating Hypomethylating Agents

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Prognostic scoring systems in MDS lack functional status measures. We sought to evaluate the influence of frailty on overall survival and care utilization in a national cohort. We conducted a retrospective study in the US Veterans Affairs Healthcare System of patients with MDS initiated on hypomethylating agents (HMAs) from 2004 ...
Anahid Hamparsumian, Jennifer La, Mayuri Dharne, Gary Gilbert, Mary T. Brophy, Nhan V. Do, Dae Hyun Kim, Jane A. Driver, Nathanael R. Fillmore, Clark DuMontier   +9 more
wiley   +1 more source

Ischemic Stroke in a Young Man: Unraveling the Domain of Myeloproliferative Disorders. [PDF]

Cureus, 2021
Hamid MAB, Sehbai AS, Tariq S.
europepmc   +1 more source

Meta‐Analysis of Imatinib Resistance in Chronic Myeloid Leukemia due to BIM Gene Deletion and Single Nucleotide Polymorphisms Reveals Ethnic Variations in Prevalence

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Background and Aim Deletion and single nucleotide polymorphisms in the BIM gene have been proposed as a potential contributor of intrinsic resistance to imatinib in patients with chronic myeloid leukemia (CML). Individual studies, particularly in East Asian population, have reported higher frequency of these gene variants and have suggested ...
Abhinav Bhattarai, Dimitri Kountouris, Sanjit Sah, Rachana Mehta, Ranjit Sah   +4 more
wiley   +1 more source

Chronotherapy in Hematological Malignancies: Evaluating the Rationale and Evidence

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Hematological malignancies remain one of the leading causes of morbidity and mortality despite advances in targeted therapies, immunotherapy, and stem cell transplantation. Emerging evidence indicates that treatment efficacy and toxicity depend not only on the choice of therapy but also on its timing relative to the patient's internal ...
Andrej Belančić, Marko Skelin, Yun Wah Lam, Almir Fajkić, Bruna Perkov‐Stipičin, Rossana Roncato, Ivan Krečak, Marko Lucijanić   +7 more
wiley   +1 more source